Keyword search (4,163 papers available)

"Gauthier S" Authored Publications:

Title Authors PubMed ID
1 Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; 39636028
HKAP
2 Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis Vianna P; Calce SI; Boustros P; Larocque-Rigney C; Patry-Beaudoin L; Luo YH; Aslan E; Marinos J; Alamri TM; Vu KN; Murphy-Lavallée J; Billiard JS; Montagnon E; Li H; Kadoury S; Nguyen BN; Gauthier S; Therien B; Rish I; Belilovsky E; Wolf G; Chassé M; Cloutier G; Tang A; 37787678
ENCS
3 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; 33532543
PERFORM
4 Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants 32725777
PERFORM
5 Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, 32582834
PERFORM
6 Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P 31530809
PERFORM
7 The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ 31309917
PSYCHOLOGY
8 Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment. Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J 28522082
PERFORM
9 Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA 28894304
PERFORM
10 Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative 29396637
PERFORM

 

Title:Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
Authors:Pascoal TATherriault JMathotaarachchi SKang MSShin MBenedet ALChamoun MTissot CLussier FMohaddes SSoucy JPMassarweh GGauthier SRosa-Neto P
Link:https://pubmed.ncbi.nlm.nih.gov/32582834/?utm_source=MS-Office&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1deGMjvjVspk9gsE
DOI:10.1002/dad2.12037
Publication:Alzheimer' s & dementia (Amsterdam, Netherlands)
Keywords:Alzheimer's diseaseamyloid betamild cognitive impairmentpositron emission tomography
PMID:32582834 Category: Date Added:2020-06-25
Dept Affiliation: PERFORM
1 Translational Neuroimaging Laboratory Alzheimer's Disease Research Unit The McGill University Research Centre for Studies in Aging McGill University Montreal Quebec Canada.
2 Department of Neurology and Neurosurgery McGill University Montreal Quebec Canada.
3 Montreal Neurological Institute Montreal Quebec Canada.
4 PERFORM Centre Concordia University Montreal Quebec Canada.

Description:

INTRODUCTION: Abnormal brain amyloid beta (Aß) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown whether the assessment of the topographical distribution of Aß pathology can provide additional information to identify, among global Aß positive individuals, those destined for dementia.




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University